Variable | Treatment group | p value |
---|
Placebo | CS-OSA |
---|
Number of patients | 10 | 8 | Â |
Number of implants | 20 | 16 | Â |
Age | 51.50 ± 10.19 | 52.50 ± 7.29 | 0.818 |
Number of males | 3 | 5 | 0.168 |
PPD (mm) | 5.04 ± 2.37 | 6.01 ± 2.54 | 0.009 |
REC (mm) | 0.78 ± 1.27 | 0.70 ± 1.22 | 0.577 |
BOP (%) | 86.67 ± 34.14 | 94.79 ± 22.34 | 0.045 |
IS-AC (mm)# | 2.57 ± 2.56 | 2.4 ± 2.19 | 0.765 |
IS-BIC (mm)# | 3.83 ± 2.39 | 4.43 ± 1.98 | 0.467 |
OHIP Total | 15.10 ± 10.81 | 14.63 ± 8.35 | 0.515 |
hsCRP (mg/L) | 2.40 ± 2.40 | 4.12 ± 2.83 | 0.055 |
Osteocalcin (ng/mL) | 9.04 ± 3.39 | 9.88 ± 3.67 | 0.762 |
BAP (µg/L) | 10.22 ± 4.20 | 10.13 ± 1.58 | 0.203 |
CTX-I (ng/mL) | 0.48 ± 0.22 | 0.52 ± 0.23 | 0.696 |
PINP (ng/mL) | 43.35 ± 12.61 | 47.03 ± 8.51 | 0.573 |
- Data expressed as mean ± SD. Significant difference between groups: p < 0.05 = significant (bold) #IS-AC and IS-BIC analysis was performed on cone beam computed tomography (CBCT) scans of sufficient quality (i.e. without artefacts) taken from 9 patients (19 implants) in the placebo group and 6 patients (7 implants) in the CS-OSA group. CS-OSA: choline-stabilized orthosilicic acid, PPD: probing pocket depth, REC: mucosal recession, BOP: bleeding on probing, IS-AC: distance from implant shoulder to alveolar crest, IS-BIC: distance from implant shoulder to first bone-to-implant contact, OHIP: patient’s oral health related quality of life questionnaire, hsCRP: high sensitive C-reactive protein, BAP: bone alkaline phosphatase, CTX-I: C-terminal telopeptide of collagen I, PINP: N-terminal propeptide of type I procollagen